Somatic Mutations and Alzheimer’s Disease

Manuscript Number: 

22-0643R1

Author(s): 
Jocelyn Downey, Illana Gozes, Jacqueline C.K. Lam, Victor O.K. Li

Disclosures

Jocelyn Downey

  • Nothing to Disclose

Illana Gozes

  • Equity:
    ATED Therapeutics Ltd, Chief Scientific Officer and a Director.
    Patents/Royalties
    1] ADNP and NAP (Davunetide) use are under patent protection, Ramot at Tel Aviv University, licensed to ATED Therapeutics Ltd. 2] Li VOK, Lam JCK, Han Y, Downey J, Kaistha T, Gozes I (2021) DeepDrug: An expert-led directed graph neural network drug-repurposing framework for identification of a lead combination of drugs protecting against Alzheimer’s Disease and related disorders. Provisional Patent US63/245,353

Jacqueline C.K. Lam

  • Patents/Royalties
    We have filed a provisional patent, cited in the paper: Li VOK, Lam JCK, Han Y, Downey J, Kaistha T, Gozes I (2021) DeepDrug: An expert-led directed graph neural network drug-repurposing framework for identification of a lead combination of drugs protecting against Alzheimer’s Disease and related disorders. Provisional Patent US63/245,353.

Victor O.K. Li

  • Patents/Royalties
    We have filed a provisional patent, cited in the paper: Li VOK, Lam JCK, Han Y, Downey J, Kaistha T, Gozes I (2021) DeepDrug: An expert-led directed graph neural network drug-repurposing framework for identification of a lead combination of drugs protecting against Alzheimer’s Disease and related disorders. Provisional Patent US63/245,353.